腹腔热灌注化疗对复发性卵巢癌预后影响的Meta分析  

Effect of hyperthermic intraperitoneal chemotherapy on prognosis of recurrent ovarian cancer: a Meta-analysis

作　　者：陶利华 李云云 李飞[1] 肖正华[1] 张晓静[1] 林英[1] 罗堂淑 TAO Li-hua;LI Yun-yun;LI Fei;XIAO Zheng-hua;ZHANG Xiao-jing;LIN Ying;LUO Tang-shu(Department of Gynecology and Obstetrics,Yongchuan Hospital Affiliated to Chongqing Medical University,Chongqing 402160,China)

机构地区：[1]重庆医科大学附属永川医院妇产科,重庆市402160

出　　处：《广西医学》2019年第6期747-750,共4页Guangxi Medical Journal

基　　金：重庆市卫生局医学科研计划(20132076)

摘　　要：目的评估腹腔热灌注化疗(HIPEC)对复发性卵巢癌(ROC)预后的影响。方法计算机检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、维普和万方等数据库,收集关于HIPEC治疗ROC的研究,对纳入研究进行质量评价。以风险比(HR)和95%可信区间(95%CI)为效应指标,采用Stata 12. 0软件进行Meta分析。结果共纳入6项研究,共计405例患者。Meta分析结果显示,HIPEC可以改善ROC患者的总生存期(P <0. 05,HR=0. 48,95%CI:0. 32,0. 71)。结论 HIPEC可以改善ROC患者的预后。Objective To evaluate the effect of hyperthermic intraperitoneal chemotherapy( HIPEC) on the prognosis of patients with recurrent ovarian cancer( ROC). Methods A computer-based retrieval was performed in databases,such as PubMed,Embase,Cochrane Library,Web of Science,CNKI,VIP,WanFang Data and so on,to collect the trials on HIPEC for treating ROC,quality assessment of the included trials was carried out. Using hazard ratio( HR) and 95% confidence interval( 95% CI) as effect indicators,Stata 12. 0 software was adopted to conduct Meta-analysis. Results A total of 6 trials involving 405 patients were included. The results of Meta-analysis showed that HIPEC could improve the overall survival of patients with ROC( P < 0. 05;HR = 0. 48;95% CI,0. 32-0. 71).Conclusion HIPEC can improve the prognosis of patients with ROC.

关 键 词：复发性卵巢癌 腹腔热灌注化疗 预后 META分析 

分 类 号：R737.31[医药卫生—肿瘤]